The developmental switch from fetal to adult hemoglobin has long fascinated biologists and attracted hematologists given its importance for patients with hemoglobin disorders. New discoveries have reinvigorated the field of globin gene regulation. These results hold promise for improved treatment of the major hemoglobinopathies.
Introduction
A maxim of pediatrics is that developmental stage influences disease expression. In few cases is this more evident than the hemoglobin disorders. Each hemoglobin tetramer is composed of two alpha-like and two beta-like globin polypeptides. Whereas deficient alpha-globin expression causes critical prenatal anemia and fetal hydrops, deficient beta-globin expression is associated with relatively mild or even silent clinical outcomes at birth with disease manifestations delayed until infancy. This disparity is because beta-globin is not a constituent of fetal hemoglobin (HbF), a tetramer of two alpha and two gamma-globin chains. Around birth, expression of gamma-globin is progressively silenced and beta-globin expression is activated. Individuals with beta-globin disorders have clinical courses whose severity is inversely proportional to the degree of preservation of HbF expression. Rare individuals with beta-hemoglobinopathies and hereditary persistence of fetal hemoglobin (HPFH) do not manifest disease [1] . (Even though fetal hemoglobin has a slightly higher affinity for oxygen than does adult hemoglobin, individuals with HPFH are completely healthy.) The structurally normal gamma-globin is able to substitute for the absent beta-globin in beta-thalasse-mia and disrupt sickle hemoglobin-associated polymerization in sickle cell disease. The most successful HbF inducer in the pharmacologic armamentarium is hydroxyurea [2, 3, 4 ] . Hydroxyurea reduces the frequency and severity of sickle cell crises and may forestall end-organ damage [5] [6] [7] . However, hydroxyurea has inconsistent effectiveness, requires careful monitoring, and has limited utility for the treatment of beta-thalassemia. There remains an unmet need for more efficient, safe, and tolerable means of HbF induction. In this context, recent advances in the understanding of the developmental regulation of globin gene expression ('hemoglobin switching') hold promise for the development of novel therapeutic strategies for beta-hemoglobinopathies.
Hemoglobin switching
Five beta-like globin genes reside in a single gene cluster (see Fig. 1 [8] ). HBE encodes epsilon-globin, expressed during early embryogenesis in primitive erythrocytes derived from the yolk sac; HBG1 and HBG2 encode gamma-globin, expressed from mid-gestation until infancy; and HBD and HBB encode delta-and beta-globin, which compose the minor and major forms of adult hemoglobin, predominating after birth. The acquisition of fetal-stage gamma-globin occurred during primate evolution, so in most animals (including the lab mouse) there are only embryonic and adult globin genes. Two hemoglobin switches occur through human ontogeny, initially from embryonic to fetal globins and later from fetal to adult. The clinically relevant aspect of the switch with regard to beta-hemoglobinopathies is the repression of gamma-globin in adult-stage erythroblasts.
Maturational switching describes the finding that initial stages of erythroid differentiation are relatively permissive for gamma-globin expression, whereas terminal stages restrict expression to beta-globin [9] . HbF production is enhanced following acute erythropoietic stress, such as after hemorrhage, hemolysis, or recovery from chemotherapy. This HbF surge may be due to the accelerated expansion of early erythroid progenitors that retain gamma-globin expression potential. Cytotoxic agents [10 ] such as hydroxyurea were first explored for use in HbF induction because of the hypothesis that they might alter the kinetics of erythropoiesis in a manner similar to 'stress erythropoiesis.'
Hereditary persistence of fetal hemoglobin is caused by two classes of mutations: one involving large deletions at the beta-globin cluster and the other involving point mutations in the promoters of the gamma-globin genes. Deletional HPFH is associated with both the loss of repressive intergenic sequences and the juxtaposition of distant enhancers [1, 11, 12 ] . Nondeletional forms of HPFH suggest that the promoters of the gamma-globin genes interact with repressive factors.
Conceptual formulations of hemoglobin switching have distinguished between autonomous and competitive modes of control. In autonomous models, gamma-globin is repressed in the adult stage due solely to the transacting environment, whereas in competitive models gamma-globin repression depends on the presence of an adjacent beta-globin gene within the cluster. Several lines of evidence support competition of endogenous human globin genes: residual HbF in the adult stage is not evenly distributed among erythrocytes but rather has a limited expression in a few red blood cells called F-cells; patients with beta-thalassemia typically demonstrate reciprocal elevations of HbF; and heterozygotes with HPFH have decreased expression of beta-globin from the affected but not the unaffected allele [13] . Each beta-globin cluster contains a distal regulatory element (known as the locus control region, or LCR) required for appropriate globin gene expression [14, 15] . The LCR participates in long-range looping interactions with individual globin genes, with only one productive LCRglobin gene interaction possible at a given time [16] . However, transgenic mice with an LCR linked solely to gamma-globin in the absence of adjacent globin genes demonstrate partial silencing during development, demonstrating that at least some of the switch is autonomous [17, 18] . Even in competitive models (in which cis-acting interactions are emphasized), some stage-specific trans-acting mechanisms must be invoked to initiate and maintain the switch.
A silencer of gamma-globin
Although intense efforts have focused on the biochemical characterization of globin gene regulation [19 ,20 ,21-25] , major breakthroughs in the field of hemoglobin switching continue to come from human genetics. Perhaps genotype-phenotype correlations are particularly instructive because the problem is limited to control of a single gene within a single lineage. Top, relative expression of beta-like globin genes through ontogeny. Bottom, schematic of the beta-globin locus, including five genes and a distal regulatory element known as the locus control region (LCR). Graph modified from [8] .
Genome-wide association studies (GWAS) take advantage of common polymorphisms to relate phenotypes to variation at discrete loci. GWAS, applied to the problem of HbF variation, have yielded consistent and striking findings, across ethnicities and among healthy individuals and those with beta-hemoglobinopathies: a meaningful fraction of the variation in HbF levels is accounted for by common polymorphisms at just three loci [26] [27] [28] [29] [30] [31] [32] . These loci include the beta-globin cluster itself (not surprising, since rare mutations here result in HPFH), an intergenic interval between the HBS1L and MYB genes (previously identified by linkage analysis of a family with elevated HbF [33] ), and BCL11A. BCL11A, not previously implicated in hemoglobin switching, was an intriguing candidate, as it is a zinc-finger transcriptional repressor active in other hematopoietic lineages (B-lymphoid cells) and expressed in erythroid cells.
Studies from our lab and others have shown that BCL11A silences gamma-globin. Knockdown of BCL11A enhances HbF production in human erythroid progenitors [34] . Knockout of BCL11A in the mouse profoundly delays the single switch from embryonic-to-adult globins as well as silencing of gamma-globin carried on a human beta-globin cluster transgene [35 ] . BCL11A does not occupy the gamma-globin promoter but binds to the LCR as well as intergenic regions in the cluster [34,36 ,37 ] previously associated with gamma-globin repression [1, 11] .
BCL11A associates with various partners within erythroid multiprotein complexes [34,36 ,37 ] , including the repressive nucleosome remodeling and deacetylase complex (NuRD), GATA1, the erythroid master regulator, and SOX6, a transcription factor previously shown to repress embryonic globins in mice [38] [39] [40] [41] . Unlike BCL11A, SOX6 directly occupies the gamma-globin promoter, and double knockdown of BCL11A and SOX6 has an additive effect on HbF derepression, suggesting that BCL11A may exert part of its gammaglobin repression with SOX6 [36 ].
Trans-acting factors important in globin gene regulation must themselves be developmentally regulated to be effectors of the physiologic switch. In the adult stage BCL11A is expressed at high levels, whereas in embryonic and fetal stages its expression level is much lower and shorter isoforms predominate [34, 35 ] . Future studies will help determine the extent to which erythroid BCL11A is subject to post-translational control such as proteolytic cleavage or SUMOylation [34, 42, 43 ] . BCL11A is also under transcriptional control [36 ], with its locus occupied by GATA1 [37 ] . Therefore BCL11A appears to be a new therapeutic target for HbF induction. One issue will be the degree to which inhibition of BCL11A has nonerythroid effects, such as in B cells.
A master erythroid regulator
The next clue in the hemoglobin switching puzzle again came from human genetics. The first hint was a patient with congenital dyserythropoeitic anemia (CDA) found to have persistently elevated HbF and a mutation in the KLF1 gene causing a single amino acid substitution in the second zinc finger of this transcription factor [44] .
Recently, a mouse mutation called Nan (for neonatal anemia) was mapped to a substitution of the equivalent zinc finger residue within KLF1 [45 ,46 ] . Heterozygous Nan mice have chronic hemolytic anemia and persistently elevated embryonic globin expression [45 ] . The Nan allele is associated with more severe phenotypes than the simple KLF1 knockout, indicating neomorphic properties. Of note, individuals with loss-offunction KLF1 mutations were known to display the In(Lu) phenotype (disturbed expression of certain blood group antigens) but were not reported to have deranged globin gene expression [47] . Subsequently, a novel form of HPFH in a Maltese kindred was mapped to heterozygous nonsense mutations in the first zinc finger of KLF1 [48 ] . Unlike the neomorphic Nan mutation, Maltese HPFH appears to be due to a haploinsufficient KLF1 allele. Further characterization will be required to compare this allele with those associated with the In(Lu) phenotype.
Knockdown of KLF1 in human erythroid progenitors derepresses HbF [48 ,49 ] . KLF1 (also known as EKLF) was first characterized as an erythroid transcription factor binding to CACCC motifs [50] . Thalassemia intermedia patients with mutations in the CACCC box of the beta-globin promoter were described nearly 30 years ago [51] , and these patients demonstrate significant elevation of HbF [52] . KLF1 is a potent activator of beta-globin in vivo, as demonstrated by knockout mice that succumb to fatal beta-thalassemia [53] [54] [55] . Careful observation of these mice (and those bearing a human beta-globin cluster transgene) prior to their death demonstrates delayed silencing of mouse embryonic globin and human transgenic gamma-globin genes in the homozygous and heterozygous KLF1 mutants [56, 57] .
Surprisingly, gene expression profiling of erythroid progenitors in patients with Maltese HPFH demonstrated decreased expression of BCL11A [48 ] . Knockdown of KLF1 led to decreased BCL11A in normal erythroid progenitors, and reexpression of KLF1 rescued BCL11A expression in erythroid progenitors of patients with Maltese HPFH [48 ] . In a parallel study, mice with a hypomorphic KLF1 allele demonstrated delayed silencing of murine embryonic globins (and transgenic human gamma-globin) and reduced BCL11A [49 ] . KLF1 occupies the BCL11A promoter [48 ,49 ] .
These studies suggest a model in which KLF1 has dual functions. First, it influences gamma-globin silencing by providing the beta-globin gene with a competitive advantage, and, second, it activates the gamma-globin silencer BCL11A. This seeming reconciliation of competitive and autonomous models begs the question of how KLF1 itself is developmentally regulated. Although KLF1 modestly increases in concentration between embryonic and adult stages [58, 59] , it is active and competent for high-level beta-globin expression in the embryonic stage [55, 60] , suggesting that layers of its regulation remain obscure. Furthermore, in mice carrying a human beta-globin cluster transgene the magnitude of gamma-globin derepression observed in KLF1 deficiency is much less than that seen in BCL11A deficiency, implying additional relevant inputs to BCL11A regulation. KLF1 not only coordinates globin gene expression but also is a regulator involved in supporting many aspects of erythroid biology [61] [62] [63] . Various KLF factors play redundant and opposing roles in vivo [60, 64] . Therefore interventions aimed at inducing HbF by inhibiting KLF1 might have a narrow therapeutic window.
The other locus highlighted by GWAS is the intergenic interval between HBS1L and MYB. Whereas studies have conflicted as to which of these two genes regulates HbF [65] [66] [67] , the weight of evidence points to c-Myb, an erythroid transcription factor [68] . A recent study demonstrated that knockdown of c-Myb during erythroid differentiation of human hematopoietic progenitors was associated with decreased expression of KLF1 [69 ] . The simple model implied by this study, that c-Myb represses gamma-globin via KLF1 activation of BCL11A, awaits experimental support.
The importance of epigenetics
Chromatin-modifying activities participate in the hemoglobin switch. The gamma-globin gene becomes methylated in the adult stage, whereas the beta-globin gene remains unmethylated [70, 71] . The gamma-globin promoter is occupied by multiprotein repressive complexes including the arginine methyltransferase PRMT5, the DNA-methylating enzyme DNMT3A, the lysine methyltransferase SUV4-20h1, the serine/threonine kinase CK2alpha, and components of NuRD [72, 73 ] . Teasing out the role of the sundry chromatin-modifying activities residing at the beta-globin cluster remains a challenge. Recent approaches have begun to scrutinize these complexes, with surprising results. NuRD appeared to be an excellent candidate for mediating repression of gammaglobin, in concert with BCL11A [34] and GATA1-FOG1 [25] , among other partners. A FOG1 mutation engineered to lack the NuRD binding domain and knocked-in to the endogenous locus does not impair transgenic human gamma-globin (or endogenous murine embryonic globin) silencing but paradoxically leads to decreased beta-globin expression [74 ] . This suggests a perplexing model in which the GATA1-FOG1-NuRD complex is required for globin activation (rather than repression). Whether NuRD plays this unforeseen role within other complexes remains to be seen.
Another insight has come from study of PRMT1, an arginine methyltransferase linked to activation of betaglobin [75] . Surprisingly, knockdown of FOP (Friend of PRMT1), a recently identified PRMT1 partner, causes significant derepression of gamma-globin [76 ] . FOP expression rises from fetal to adult stages, suggesting it might participate in the physiologic switch. Numerous questions remain regarding the function of this factor, including whether these effects are through PRMT1 or other methyltransferases, or via an altogether different pathway.
The physiologic switch depends on the interplay between the erythroblast-intrinsic machinery and signals emanating from the stage-specific niche. A population of fetal hepatic stromal cells has recently been identified that support hematopoietic cells by expressing cytokines such as stem cell factor (SCF), which are differentially regulated in fetal liver compared with bone marrow [77 ] . SCF promotes maintenance of HbF expression [78, 79] and this cytokine alters the distribution of histone marks within the beta-globin cluster [80 ] . The SCF receptor decreases on erythroid progenitors from fetal to adult life, targeted by the adult stage-specific micro-RNAs miR-221 and miR-222 [81 ] .
Beginnings of a network
A host of new players implicated in repressing HbF present as therapeutic targets for the treatment of beta-hemoglobinopathies (see Fig. 2 ). A critical task will be to place these factors into a unified hierarchy, comparing various regulators in terms of quantitative effects on globin expression, relationships to other factors, nonglobin effects on erythropoiesis, and impacts outside the erythroid lineage. A granular network of HbF regulatory pathways will help prioritize the most promising leads for further clinical development.
Key regulators of the globin switch may serve as direct targets for small molecules. DNA-binding transcription factors such as BCL11A or KLF1 have been considered challenging targets for drug development although recent advances may extend the reach of small molecules [82] . Since these transcription factors cooperate with chromatin modifying activities, traditional enzyme inhibitors may also have a role in HbF induction. The imperative will be to define activities that have limited effects outside hemoglobin switching. Demethylating agents have been explored; promising results with 5-azacytidine in a beta-thalassemia patient were noted nearly 30 years ago [83] . Decitabine, a demethylator with a more encouraging safety profile, has shown impressive HbF induction in primate models [43 ] and remains in clinical development. Histone deacetylase inhibitors also have potential to induce HbF [84] [85] [86] . A recent study integrated highthroughput cell-based screening, an extensive library of HDAC inhibitors, and RNA interference, to define HDAC1 and HDAC2 as the specific deacetylases responsible for HbF repression [87 ] . Selective HDAC modulators might achieve HbF induction while avoiding toxicity. Advanced chemical biology methods may allow agnostic screens to probe undiscovered pathways influencing the globin switch.
Genetic and cellular therapeutics may also have a role. Such strategies could include the in-vivo application of RNA interference [88] , engineered transcription factors [89] , or the use of stem cells [90] . Recently an artificial transcription factor targeting the gamma-globin promoter was shown to derepress HbF [91 ] . This form of gene correction in trans is one of many potential strategies to reverse the switch.
Conclusion
The study of hemoglobin switching was reinvigorated by the recent discovery of BCL11A as a potent silencer of gamma-globin. The finding that KLF1 promotes fetal hemoglobin repression through activation of both betaglobin and BCL11A assimilates competitive and autonomous models. A tentative network of fetal hemoglobin regulation materializes, involving c-Myb, KLF1, and BCL11A, and integrating epigenetic mechanisms with extrinsic influences. Despite great progress in the field, only half the variance in fetal hemoglobin levels has been explained, suggesting uncharted insights will help clarify the system and prioritize clinical development. 
12
Gazouli M, Katsantoni E, Kosteas T, Anagnou NP. Persistent fetal gammaglobin expression in adult transgenic mice following deletion of two silencer elements located 3' to the human Agamma-globin gene. Mol Med 2009; 15:415-424. Using detailed transgenic studies, the authors describe a cis element repressing gamma-globin expression in the adult stage. Future studies using similar transgenes will help define the interactions that establish hemoglobin switching in vivo; for example, it is possible that BCL11A exerts its gamma-globin repressive effect via interactions with such cis elements.
Update on fetal hemoglobin gene regulation Bauer and Orkin 5 This study, along with that of Jawaid et al., uses high-resolution ChIP-chip to show that BCL11A binds to the beta-globin cluster not at the gamma-globin or betaglobin genes themselves but at distant sites, including the LCR and gamma-delta intergenic intervals. BCL11A is shown to promote long-range interactions between the LCR and HBB at the expense of HBG. BCL11A also interacts with SOX6, a known repressor of murine embryonic globins. SOX6 is shown to repress gamma-globin in adult human erythroid progenitors and to occupy the gammaglobin promoter. Therefore, BCL11A may act with various partners to effect repression of gamma-globin. Future experiments will help characterize the critical multiprotein complexes and beta-globin regulatory sequences through which BCL11A represses gamma-globin.
37
Jawaid K, Wahlberg K, Thein SL, Best S. Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus. Blood Cells Mol Dis 2010; 45:140-146. This important study using high-resolution ChIP-chip in human adult erythroid progenitors confirms that BCL11A, although occupying the beta-globin cluster, occupies neither the gamma-globin nor the beta-globin promoter. Rather, BCL11A occupies important regulatory regions including the LCR and several loci in the gamma-delta intergenic interval. Furthermore, BCL11A and GATA-1 often appear to share co-occupancy, indicating they may participate in a multisubunit complex. GATA1 binds to intronic regions of the BCL11A gene, adjacent to HbF-associated SNPs, suggesting that these polymorphisms mark key regulatory elements. 
45
Siatecka M, Sahr KE, Andersen SG, et al. Severe anemia in the Nan mutant mouse caused by sequence-selective disruption of erythroid Kruppel-like factor. Proc Natl Acad Sci U S A 2010; 107:15151-15156. The ENU-induced Nan (neonatal anemia) allele is mapped to a missense mutation of KLF1 affecting an equivalent residue in the second zinc finger as a human KLF1 mutation causing congenital dyserythropoietic anemia and elevated HbF. Unlike the KLF1 þ/À mouse, the Nan heterozygote is anemic with persistent embryonic globin expression, and the Nan homozygote is embryonic lethal at an earlier stage than is the KLF1 null mouse, suggesting that the Nan allele has neomorphic or dominant negative properties, apparently due to altered DNA-binding specificity. This study confirms the role of KLF1 in hemoglobin switching and highlights that various KLF1 alleles have disparate erythroid phenotypes.
46
Heruth DP, Hawkins T, Logsdon DP, et al. Mutation in erythroid specific transcription factor KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model. Genomics 2010; 96:303-307. This study, like that of Siatecka et al., maps the Nan mutation to KLF1. The authors propose a model in which this mutant encodes an abnormal KLF1 protein with altered DNA-binding properties.
